Collegium Pharmaceutical, Inc. (FRA:354)

Market Cap	894.10M +6.0%
Revenue (ttm)	664.81M +23.6%
Net Income	53.55M -9.1%
EPS	1.48 -6.6%
Shares Out	n/a
PE Ratio	16.70
Forward PE	3.49
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	n/a
Open	28.60
Previous Close	28.00
Day's Range	28.60 - 28.60
52-Week Range	22.00 - 42.00
Beta	n/a
RSI	30.62
Earnings Date	May 7, 2026

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. The company’s portfolio includes Jornay PM, a central nervous system stimulant prescription medicine that contains methylphenidate HCl for the treatment of attention deficit hyperactivity disorder; Belbuca, a buccal film that contains buprenorphine for severe and persistent pain that requires an extended treatment period; Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxyco...

• Industry: Pharmaceutical Preparations
• Founded: 2002
• Employees: 423
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 354

Financial Performance

In 2025, Collegium Pharmaceutical's revenue was $780.57 million, an increase of 23.62% compared to the previous year's $631.45 million. Earnings were $62.87 million, a decrease of -9.13%.

Financial numbers in USD